The New England Journal of Medicine backs a 2010 study at the center of a controversy involving CareFusion's ChloraPrep antiseptic, the National Quality Forum and an alleged scheme to pay kickbacks to patient safety advocate Dr. Charles Denham.
A review by the New England Journal of Medicine of data from a 2010 study it published on CareFusion's (NYSE:CFN) ChloraPrep antiseptic found that both the company and the doctor in charge of the study acted appropriately, the journal told MassDevice.com today.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1fuZWOs
Cap comentari:
Publica un comentari a l'entrada